Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Asthma
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Asthma
    Nitric Oxide Monitoring Does Not Help Most Children With Asthma - (DGNews)
    TopAbstracts in Asthma 01/05/2009 - (DGNews)
    TopAbstracts in Asthma 12/29/2008 - (DGNews)
    Itraconazole Benefits Patients With Severe Asthma, Sensitivity to Fungi - (DGNews)
    TopAbstracts in Asthma 12/22/2008 - (DGNews)

    News archive

     Recent webcasts/CME - Asthma
    • Balancing Patient-Related Factors With Safety and Efficacy to Optimize the Treatment of COPD
    • What to Look for in Future Treatments for COPD
    • Role of the Pharmacist in Optimizing the Management of Asthma: Focus on Patient Education with Inhalation Devices
      Asthma Treatment Guidelines and Use of Inhalers
      New Guidelines for the Diagnosis and Management of Asthma

      Webcasts/CME archive

       Recent cases - Asthma
        Bronchial Carcinoid in a 39-Year-Old Man Treated for Bronchial Asthma: A Case Report
        Glucocorticoid Hypersensitivity as a Rare but Potentially Fatal Side Effect of Paediatric Asthma Treatment: A Case Report
        A Case of Lactic Acidosis Complicating Assessment and Management of Asthma
        Role of Vasopressin in the Treatment of Anaphylactic Shock in a Child Undergoing Surgery for Congenital Heart Disease: A Case Report
        Isolated Left Lung Aplasia with Bronchial Asthma

        Cases archive
          




        my personal edition > asthma > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Novel Beta Agonist Indacaterol Safe and Effective in Short-Term Studies of Patients With Persistent Asthma: Presented at ACAAI

        By Corinna S. Bowser, MD

        PHILADELPHIA, PA -- November 20, 2006 -- The novel, once-daily, long-acting beta agonist indacaterol has demonstrated safety and efficacy for treatment of persistent asthma in 7- and 28-day studies, according to researchers speaking here at the 2006 Annual Meeting of the American College of Allergy, Asthma and Immunology (ACAAI).

        "Ultimately, if you can put this with a once-a-day topical steroid, that's as good an you're going to get, and that's what everybody's holy grail would be -- once-a-day therapy with a combination treatment," said investigator Craig F. LaForce, MD, clinical professor of pediatrics, University of North Carolina School of Medicine, Chapel Hill, and medical director, North Carolina Clinical Research, Chapel Hill, North Carolina.

        Current combination treatments, such as fluticasone/salmeterol (Advair Diskus) and budesonide/formoterol (Symbicort) are given twice daily, and according to Dr. LaForce, the requirement for twice daily dosing is an issue that may impact patient compliance with treatment.

        In their randomized, double-blind, placebo-controlled, dose-ranging study, Dr. LaForce and colleagues evaluated indacaterol in a cohort of 436 patients with persistent asthma that was stable on inhaled corticosteroids.

        Patients were randomized to 7 days of treatment with indacaterol at 50, 100, 200, or 400 mg, or placebo, given via a multi-dose dry-powder inhaler.

        For all doses of indacaterol, adjusted mean forced expiratory volume in 1 second (FEV1) was higher than in the placebo group (P < .001) at all time points measured on days 1 and 7. The predose differences between treatment and placebo in adjusted mean FEV1 on day 7 ranged from 210 to 310 mL (P < .05 vs placebo).

        Most adverse events were mild to moderate, with 2 patients discontinuing due to adverse events that may have been related to indacaterol. There were no serious adverse events or deaths.

        This study was supported by Novartis Pharma AG.


        [Presentation title: Safety and Efficacy of Indacaterol, a Novel Once-Daily B2-Agonist, in Patients With Persistent Asthma. Abstract P162]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send